Gossamer Bio’s Promising Clinical Advances and Strong Financial Position Justify Buy Rating

Gossamer Bio (GOSS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock and has a $10.00 price target.

Patrick Trucchio has given his Buy rating due to a combination of factors surrounding Gossamer Bio’s promising developments in their clinical programs. The company’s lead candidate, seralutinib, is advancing through late-stage trials, with the Phase 3 PROSERA trial for pulmonary arterial hypertension fully enrolled and expected to deliver top-line data in early 2026. This trial is designed to assess seralutinib’s efficacy in a population with severe disease, which could demonstrate significant treatment benefits.
Additionally, the upcoming SERANATA trial for pulmonary hypertension with interstitial lung disease is set to begin in late 2025, exploring higher doses of seralutinib to potentially enhance its therapeutic impact. Gossamer Bio’s strong financial position, bolstered by a strategic partnership with Chiesi and substantial cash reserves, supports the continued development of seralutinib, which is seen as a best-in-class inhaled kinase inhibitor with the potential to address significant unmet medical needs. These factors collectively underpin Trucchio’s optimistic outlook and Buy rating for Gossamer Bio’s stock.

In another report released on May 16, Piper Sandler also maintained a Buy rating on the stock with a $15.00 price target.